ArticleTherapeutic advances in endocrinology and metabolism2026
Determination of the relationship between raftlin, oxidative stress levels, and vitamin D receptor gene polymorphism in diabetic patients.
Article in Therapeutic advances in endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pathogenesis of diabetes is affected by a complex interplay between numerous environmental and genetic factors. While single-nucleotide polymorphisms (SNPs) are not directly used as biomarkers of the disease, they can be considered an important guide for determining predisposition. Objective: To investigate the roles of raftlin, malondialdehyde (MDA), superoxide dismutase (SOD), and the vitamin D receptor (VDR) BsmI (rs1544410 A>G) polymorphism, in the clinical progression of type 2 diabetes mellitus (T2DM). Design: A retrospective observational case-control study. Methods: A total of 300 subjects were included in the study: 104 with T2DM, 85 with prediabetes, and 111 healthy controls. The VDR BsmI polymorphism was genotyped using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method, while serum MDA, SOD, and raftlin were analyzed via the enzyme-linked immunosorbent assay (ELISA) method. Results: No statistically significant differences were observed in the allelic and genotype frequencies of the VDR gene BsmI polymorphism between T2DM prediabetes patients and controls ( Conclusion: To the best of our knowledge, this is the first study to demonstrate that raftlin exhibits significant diagnostic efficacy in individuals with the bb genotype within a clinical T2DM cohort.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.